Through a science-led approach and extensive experience in product development, Upperton’s team can support you with aseptic and terminally sterilised small volume liquids, as well as lyophilised and spray dried powders for parenteral, ocular and pulmonary delivery.
Our contract manufacturing capabilities and successful regulatory history supports you in maximising the success of your drug product. We excel in facilitating rapid product selection for clinical evaluation, backed by a comprehensive package designed to de-risk and scale-up later-stage development.
Upperton鈥檚 sterile processing services include:
- Sterile drug products: Both aseptically prepared and terminally sterilised
- Liquid formulations: Suitable for parenteral, ocular, and pulmonary delivery
- Wide range of molecules: Includes small molecules, biologics, proteins, peptides, and monoclonal antibodies
- Lyophilised and spray-dried powders: Aseptically prepared for enhanced stability
Purpose-built sterile facility
- 7,000ft虏 purpose-built GMP sterile manufacturing facility
- Designed specifically in line with the revised (August 2023) EU GMP Annex-1 regulations
- Advanced VHP Isolator barrier technology
Sterile fill/finish services
- Formulation development and stability testing
- Aseptic preparation and terminally sterilised products
- Batch sizes of up to 2,000 units
- Filling of vials and pre-filled syringes
- CMC sterility assurance package
Production area
- Two purpose-designed processing rooms
- VHP processing isolators
- Dedicated isolators for lyophilisation and spray-drying
- Depyrogenation ovens and autoclaves
- Visual inspection room